In vivo RNAi for target validation in oncology

被引：0
|
作者：
Seibler, Jost
Ewa, Michalak
Karim, Nacerddine
van Lohuizen, Maarten
Jos, Jonkers
机构：
[1] TaconicArtemis GmbH, Cologne, Germany
[2] Netherlands Canc Inst, Div Mol Biol, Amsterdam, Netherlands
来源：
BULLETIN DU CANCER | 2010年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [21] Challenges for RNAi in vivo
    Paroo, Z
    Corey, DR
    [J]. TRENDS IN BIOTECHNOLOGY, 2004, 22 (08) : 390 - 394
  • [22] RNAi in vivo technologies
    Kuehn, R.
    Steuber-Buchberger, P.
    Delic, S.
    Sujeva, V
    Wefers, B.
    Wurst, W.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 19 - 19
  • [23] Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing
    Luo, Qing
    Kang, Quan
    Song, Wen-Xin
    Luu, Hue H.
    Luo, Xiaoji
    An, Naili
    Luo, Jinyong
    Deng, Zhong-Liang
    Jiang, Wei
    Yin, Hong
    Chen, Jin
    Sharff, Katie A.
    Tang, Ni
    Bennett, Erwin
    Haydon, Rex C.
    He, Tong-Chuan
    [J]. GENE, 2007, 395 (1-2) : 160 - 169
  • [24] Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation
    Chatterjee-Kishore, M
    Miller, CP
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (22) : 1559 - 1565
  • [25] Current efforts in the analysis of RNAi and RNAi target genes
    Bengert, P
    Dandekar, T
    [J]. BRIEFINGS IN BIOINFORMATICS, 2005, 6 (01) : 72 - 85
  • [26] The Translational Potential for Target Validation and Therapy Using Intracellular Antibodies in Oncology
    Weidle, Ulrich H.
    Maisel, Daniela
    Brinkmann, Ulrich
    Tiefenthaler, Georg
    [J]. CANCER GENOMICS & PROTEOMICS, 2013, 10 (06) : 239 - 250
  • [27] Validation of PERK as an oncology target: A role for the unfolded protein response in cancer
    Dellamaggiore, Ken
    Mitchell, Petia
    Sun, Ji-Rong
    Jones, Jeffrey
    Muchamuel, Tony
    Hollenback, David
    Tadesse, Seifu
    Booker, Shon
    Hong, Fang-Tsao
    Smith, Adrian
    Rose, Mark
    Beltran, Pedro
    Lipford, James R.
    [J]. CANCER RESEARCH, 2016, 76
  • [28] NOVEL, SELECTIVE MNK INHIBITORS AS IMPROVED TOOLS FOR ONCOLOGY TARGET VALIDATION
    Bureau, E. A.
    Newman, M.
    Adigun, S.
    Langham, C.
    Carnevalli, L.
    Ruston, L.
    Howard, Z.
    Bakrania, P.
    Kamal, A.
    Lewis, S.
    Osborne, J.
    Brownlees, J.
    Winter, J.
    McIver, E.
    Saxty, B.
    Hudson, K.
    Merritt, A.
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 5853 - 5854
  • [29] RNAi invigorates target ID & validation efforts - As enabling tool & potential therapeutic, RNAi opens avenues for research service providers & pharmas
    Kerr, E
    [J]. GENETIC ENGINEERING NEWS, 2004, 24 (01): : 20 - +
  • [30] Application of RNA interference (RNAi) technology for target validation in cultured human tissue explants.
    Song, Lily
    Tortorella, Micky
    Malfait, Anne-Marie
    Amer, Elizabeth
    Griggs, David W.
    [J]. ACTA PHARMACOLOGICA SINICA, 2006, 27 : 256 - 256
12345